Inaccurate PASARR Screening and Missing Level II Evaluations
Summary
The facility failed to ensure accurate PASARR screening for residents with mental disorders, intellectual disability, or related conditions. Based on record review and interviews, five of six residents reviewed had PASARR records that did not match their diagnoses or did not contain required Level II evaluations when indicated. The deficiency involved residents with diagnoses including dementia, bipolar disorder, depression, anxiety, psychotic disorders, epilepsy, alcohol dependence, and Parkinson’s disease-related psychosis. For one resident, the Level I PASARR listed depressive disorder, but the medical record also showed psychotic disorder with hallucinations, unspecified dementia with mood disturbance, depression, epilepsy, and use of psychotropic medications including sertraline, donepezil, quetiapine, and lorazepam. No Level II PASARR evaluation or determination was found. Another resident’s record showed epilepsy, generalized anxiety disorder, dementia, mood disorder due to a physiological condition, major depressive disorder, and unspecified psychosis, with orders for lorazepam and valproic acid; the Level I PASARR listed depressive disorder, anxiety disorder, and mood disorder, but no Level II evaluation or determination was found. A third resident had diagnoses of bipolar disorder and major depressive disorder, with orders for trazodone and oxcarbazepine, yet the Level I PASARR only marked anxiety and depressive disorder and no Level II evaluation or determination was found. A fourth resident’s record showed psychotic disorder with delusions due to a physiological condition, dementia with behavioral disturbance, and adjustment disorder with anxiety, while the Level I PASARR listed Parkinson’s disease and dementia but did not include psychotic disorder, and no Level II evaluation or determination was found. A fifth resident’s Level I PASARR showed no diagnoses marked under MI or suspected MI, even though the record included alcohol dependence with withdrawal and dementia, and the resident was receiving quetiapine and anti-psychotic behavior monitoring. During interview, the Social Service Director stated she reviewed Level I PASARRs against hospital records and diagnoses, kept a log for updates, and relied on others with system access to make changes; she also acknowledged that some residents’ PASARRs needed to be updated and that certain diagnoses, such as dementia, bipolar disorder, epilepsy, and psychotic disorder, should have been reflected and may have required Level II evaluation.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.